Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

Balance Sheet As On 31st March, 2025

	Particulars	Figures as at the end of 31/03/2025
		(in Rs.)
A	**EQUITY AND LIABILITIES**	
1	**Shareholders' funds**	
	(a) Share capital	8,867,500.00
	(b) Reserves and surplus	-34,506,327.94
	(b) Money Received against share warrents	-
2	**Share application money pending allotments**	-
3	**Non-current liabilities**	
	(a) Long-term borrowings	26,630,921.58
	(b) Deferred tax liabilities (net)	-
	(c) Other Long Term Liabilities	-
	(d) Long term provision	-
4	**Current liabilities**	
	(a) Short Term Borrowings	
	(b) Trade payables	15,941,972.79
	(c) Other current liabilities	-
	(d) Short-term provisions	-
	TOTAL	**16,934,066.43**
B	**ASSETS**	
1	**Non-current assets**	
	(a) (i) Property, Plant and Equipment	12,261,008.33
	(ii) Intangible assets	-
	(iii) Capital Work in progress	-
	(iv) Intangible Assets under Development	
	(b) Non-current investments	
	(c) Deferred Tax Assets	-
	(d) Long term loans and Advances	
	(e) Other Non Current Assets	
2	**Current assets**	
	(a) Current Investments	-
	(b) Inventories	-
	(c) Trade receivables	-
	(d) Cash and cash equivalents	4,673,058.11
	(e) Short-term loans and advances	-
	(f) Other Current Assets	-
	TOTAL	**16,934,066.44**

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
Director

Sd/-
Rajendra Singh Golan
Director

Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH 2025

	Particulars	Figures for the year ended 31/03/2025
		(in Rs.)
I	Revenue from operations	-
II	Other Income	-
III	**Total Income (I+II)**	**-**
IV	**Expenses**	
	(a) Cost of materials consumed	-
	(b) Purchase of Stock in Trade	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-
	(d) Employee benefits expenses	240,375.64
	(e) Finance costs	-
	(f) Depreciation and amortisation expenses	311,175.23
	(g) Other expenses	318,972.08
	Total Expenses	**870,522.95**
V	**Profit before exceptional and extraordinary iteam and tax**	**(870,522.95)**
VI	**Exceptional Iteams**	-
VII	**Profit before extraordinary iteam and tax**	**(870,522.95)**
VIII	**Extraordinary Iteams**	-
IX	**Profit before Tax**	**(870,522.95)**
X	**Tax Expense:**	
	(a) Current tax expense	-
	(b) Deferred tax	-
	(c) Income tax relating to previous year	-
XI	**Profit / (Loss) for the period from continuing operations**	**(870,522.95)**
XII	**Other Comprehensive Income**	(80,800.00)
XIII	**Total Other Comprehensive Income (net of tax)**	**(951,322.95)**
XIV	**Profit / (Loss) from discontinuing operations**	**-**
XV	**Tax from discontinuing operations**	**-**
XVI	**Profit/ (Loss) from discontinuing operations**	

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
Director

Sd/-
Rajendra Singh Golan
Director